Wedbush Has Negative Outlook of Zenas BioPharma Q3 Earnings

Key Points

• Wedbush has reduced its Q3 2025 EPS estimate for Zenas BioPharma to ($1.33) per share, down from a previous estimate of ($1.04), while maintaining an "Outperform" rating and a target price of $35.00.
• The company's stock opened at $16.76, with a market cap of approximately $705.76 million and a PE ratio of -4.72.
• Zenas BioPharma missed analysts' consensus estimates for the most recent quarter, reporting ($1.25) EPS compared to expectations of ($1.02).

Zenas BioPharma, Inc. (NASDAQ:ZBIO - Free Report) - Analysts at Wedbush cut their Q3 2025 earnings estimates for Zenas BioPharma in a research report issued on Tuesday, August 12th. Wedbush analyst M. Fan now anticipates that the company will post earnings of ($1.33) per share for the quarter, down from their prior estimate of ($1.04). Wedbush currently has a "Outperform" rating and a $35.00 target price on the stock. Wedbush also issued estimates for Zenas BioPharma's Q4 2025 earnings at ($1.13) EPS, FY2025 earnings at ($4.51) EPS, Q1 2026 earnings at ($1.14) EPS, Q2 2026 earnings at ($1.15) EPS, Q3 2026 earnings at ($1.17) EPS, Q4 2026 earnings at ($1.18) EPS, FY2026 earnings at ($4.64) EPS, FY2027 earnings at ($4.41) EPS, FY2028 earnings at ($3.02) EPS and FY2029 earnings at ($1.20) EPS.

ZBIO has been the topic of several other research reports. HC Wainwright reiterated a "buy" rating and issued a $30.00 price target on shares of Zenas BioPharma in a research note on Friday, May 16th. Wall Street Zen downgraded Zenas BioPharma from a "hold" rating to a "sell" rating in a report on Saturday. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $36.67.

Zenas BioPharma Trading Down 2.1%

NASDAQ:ZBIO traded down $0.34 on Friday, reaching $15.51. The stock had a trading volume of 59,872 shares, compared to its average volume of 180,200. The stock's 50-day moving average price is $12.92. The company has a market cap of $653.13 million and a PE ratio of -4.37. Zenas BioPharma has a 12-month low of $5.83 and a 12-month high of $26.25.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($1.25) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.23).

Institutional Trading of Zenas BioPharma

Institutional investors and hedge funds have recently modified their holdings of the business. Intech Investment Management LLC lifted its position in shares of Zenas BioPharma by 13.9% in the 2nd quarter. Intech Investment Management LLC now owns 13,206 shares of the company's stock worth $128,000 after buying an additional 1,607 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in Zenas BioPharma by 41.2% during the second quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company's stock worth $89,000 after acquiring an additional 2,679 shares during the period. Bank of America Corp DE lifted its holdings in Zenas BioPharma by 32.3% in the second quarter. Bank of America Corp DE now owns 13,991 shares of the company's stock worth $136,000 after acquiring an additional 3,412 shares during the last quarter. New York State Common Retirement Fund bought a new position in Zenas BioPharma in the first quarter worth about $49,000. Finally, Rhumbline Advisers boosted its stake in Zenas BioPharma by 71.3% in the second quarter. Rhumbline Advisers now owns 19,721 shares of the company's stock valued at $191,000 after acquiring an additional 8,207 shares during the period.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.